Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 149Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Non-Hodgkin 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 81Hodgkin Disease 81Small Cell Lung Carcinoma 79Leukemia, Myeloid, Acute 73Burkitt Lymphoma 69Lymphoma, Follicular 67Lymphoma, Mantle-Cell 65Lung Neoplasms 60Lymphoma, Large-Cell, Immunoblastic 54Leukemia, Lymphocytic, Chronic, B-Cell 47Recurrence 40Multiple Myeloma 39Lymphoma, B-Cell, Marginal Zone 36Neuroblastoma 33Congenital Abnormalities 29Carcinoma, Non-Small-Cell Lung 28Lymphoma, B-Cell 25Myelodysplastic Syndromes 24Lymphoma, Large-Cell, Anaplastic 23Lymphoma, Extranodal NK-T-Cell 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Brain Neoplasms 22Sarcoma 21Ovarian Neoplasms 21Lymphoma, T-Cell, Peripheral 20Central Nervous System Neoplasms 20

Interventions

Docetaxel 3Prednisone 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1PE regimen 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Refractory Prostate Cancer × Etoposide × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡